SPARC (secreted protein, acidic and rich in cysteine), a new target for the treatment and prevention of acute liver failure
US10385114B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 5, 2014 |
| Grant date | Aug 20, 2019 |
| Priority date | — |
| Expiry date | Oct 3, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15043
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The invention relates to the identification of Secreted Protein, Acidic and Rich in Cysteine (SPARC) as a new therapeutic target in patients with fulminant hepatitis and allows the development of a strategy destined to protect the liver form damage. The invention relates to the treatment of acute liver failure or fulminant hepatitis by administering to a subject in need thereof an agent that inhibits at least partially the expression of SPARC and/or interferes with its biological function.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.